Myasthenia gravis is a neuromuscular junction disorder with a hallmark of progressive muscle weakness and frequent ...

Generalized myasthenia gravis (gMG) affects most patients through a handful of well-characterized neuromuscular junction ...

The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion/AstraZeneca’s eculizumab (Soliris) for pediatric patients ...

Decreased AChR-Ab titers correlated with improved myasthenia gravis symptoms, especially in ADL scores, within the first 3 months of treatment. The study found no baseline correlation between AChR ...

Welcome, everyone. I'm Dr. John Whyte, the Chief Medical Officer at WebMD. Today, I want to discuss myasthenia gravis. It's a rare autoimmune neuromuscular disease that causes weakness and fatigue ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Recently approved treatments for generalized myasthenia gravis (gMG), including complement and neonatal Fc receptor ...

I'm Dr. John Whyte, the Chief Medical Officer of WebMD. Today, I want to talk about a serious autoimmune condition called myasthenia gravis. It comes from the Latin and Greek which means grave ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hopes will shake up the ...